A compound selected from those of formula (I):
##STR1##
wherein:
- X1, X2, and X3, represent N or CR3
in which R3 is as described in the description,
- G1 represents a group selected from those of formulae (i/a)
and (i/b):
##STR2##
in which R4, R5, and R6 are as defined in the description,
- G2 represents a group selected from carboncarbon
triple bond, CHCCH, CO, CS, S(O)n1
in which n1 represents an integer from 0 to 2 inclusive, or a group of formula
(i/c):
##STR3##
in which Y1 represents O, S, NH or -Nalkyl, and Y2 represents
O, S, NH or -Nalkyl,
- n is an integer from 0 to 6 inclusive, and m is an integer from 0 to
7 inclusive,
- Z1 represents CR9R10, wherein
R9 and R10 are as defined in the description,
- A represents a ring system,
- R1 represents a group selected from H, alkyl, alkenyl, alkynyl,
optionally substituted and the group of formula (i/d):
##STR4##
in which p, Z2, B, q and G3 are as defined in the description
and optionally, its optical isomers, N-oxide, and addition salts thereof with a
pharmaceutically-acceptable acid or base, and medicinal products containing the
same are useful as specific inhibitors of type-13 matrix mettaloprotease.
|
|
|
